Aphria Inc (NYSE:APHA) Expected to Post Quarterly Sales of $99.49 Million

Equities analysts predict that Aphria Inc (NYSE:APHA) will post sales of $99.49 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aphria’s earnings. The highest sales estimate is $104.13 million and the lowest is $94.85 million. Aphria posted sales of $96.12 million in the same quarter last year, which suggests a positive year-over-year growth rate of 3.5%. The firm is scheduled to announce its next earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Aphria will report full year sales of $383.65 million for the current year, with estimates ranging from $372.02 million to $402.93 million. For the next year, analysts anticipate that the company will post sales of $504.92 million, with estimates ranging from $432.26 million to $576.11 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Aphria.

Aphria (NYSE:APHA) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.06. The business had revenue of $144.40 million for the quarter, compared to analyst estimates of $130.74 million. Aphria had a net margin of 5.75% and a negative return on equity of 0.30%. The firm’s revenue for the quarter was up 96.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.20) EPS.

Several equities analysts have recently issued reports on APHA shares. Eight Capital raised shares of Aphria to a “buy” rating in a research note on Thursday, April 16th. Alliance Global Partners restated a “buy” rating and issued a $9.00 price target (down from $11.00) on shares of Aphria in a report on Wednesday, April 15th. Cantor Fitzgerald lifted their price objective on shares of Aphria from $9.50 to $9.85 and gave the company an “overweight” rating in a report on Friday, May 8th. Bank of America boosted their price target on shares of Aphria from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Finally, Zacks Investment Research lowered shares of Aphria from a “buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $7.71.

NYSE:APHA traded down $0.16 on Monday, hitting $4.07. The company had a trading volume of 3,460,600 shares, compared to its average volume of 6,526,876. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 47.44 and a beta of 2.19. The company has a current ratio of 5.19, a quick ratio of 3.73 and a debt-to-equity ratio of 0.25. The firm has a 50 day moving average of $4.09 and a two-hundred day moving average of $4.06. Aphria has a 52 week low of $1.95 and a 52 week high of $7.60.

Large investors have recently modified their holdings of the company. PNC Financial Services Group Inc. raised its stake in Aphria by 64.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,681 shares of the company’s stock worth $26,000 after acquiring an additional 3,392 shares during the period. Moser Wealth Advisors LLC bought a new stake in Aphria during the 4th quarter worth approximately $52,000. Cetera Investment Advisers bought a new stake in Aphria during the 1st quarter worth approximately $32,000. Alpine Global Management LLC bought a new stake in shares of Aphria during the first quarter valued at approximately $33,000. Finally, BerganKDV Wealth Management LLC raised its position in shares of Aphria by 32.0% during the first quarter. BerganKDV Wealth Management LLC now owns 11,950 shares of the company’s stock valued at $36,000 after buying an additional 2,900 shares during the last quarter. Hedge funds and other institutional investors own 9.57% of the company’s stock.

Aphria Company Profile

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Further Reading: How Buying a Call Option Works

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.